Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069522 | 0.94 | CA12 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9069552 | 0.92 | TK2 (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30475852 | 0.89 | LMNA (0.56) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL30475853 | 0.89 | LMNA (0.56) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL5074670 | 0.89 | LMNA (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL25402244 | 0.87 | LMNA (0.50) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL26751632 | 0.87 | LMNA (0.50) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL7398474 | 0.87 | SLC28A1 (0.44) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL16349804 | 0.86 | P2RY6 (0.54) | P2RY6P2RY2P2RY12P2RY4P2RY14 | |
| SCHEMBL25400255 | 0.85 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105498-B2 | Acylated uridine and cytidine and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-09-12 | — | — | US | claimed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | claimed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | claimed |
| JP-2894610-B2 | — | — | 1999-05-24 | — | — | JP | claimed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | claimed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | claimed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | claimed |
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | COGNIS IP MANAGEMENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160554-A1 | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same | RNASEL, RNASEH1, DUT | CA12 2889/4885CA1 3747/4885CA2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.